Chylothorax related to acute SARS-CoV-2 infection in a patient with Noonan syndrome with prior uncomplicated cardiac surgeries.
Lubaina EhsanJessica A ThoeJohn J ParentJoseph D FakhouryPublished in: Cardiology in the young (2023)
SARS-CoV-2 is a novel coronavirus that has rarely been associated with chylothorax. Patients with Noonan syndrome are at risk for developing chylothorax, especially after cardiothoracic interventions. We present the case of SARS-CoV-2 infection triggering the underlying tendency of a patient with Noonan syndrome to develop chylothorax who did not develop it even after prior cardiothoracic interventions. Patient presented in respiratory distress without hypoxia and was found, on imaging, to have a large right-sided pleural effusion, which was eventually classified as chylothorax. The patient was then started on a low-fat diet. Chest tube drainage substantially reduced the effusion in size, and it remained stable. Our report highlights that SARS-CoV-2 infection can cause the development of a chylothorax or a chylous effusion in patients with Noonan syndrome or among populations with a similar predisposition. A high index of suspicion in vulnerable patients or those not responding to traditional therapy should exist with providers, thus leading to the testing of the fluid to confirm the diagnosis.
Keyphrases
- case report
- sars cov
- physical activity
- respiratory syndrome coronavirus
- end stage renal disease
- chronic kidney disease
- adipose tissue
- high resolution
- newly diagnosed
- left ventricular
- prognostic factors
- weight loss
- stem cells
- mass spectrometry
- mesenchymal stem cells
- intensive care unit
- bone marrow
- atrial fibrillation
- hepatitis b virus
- smoking cessation
- cell therapy
- mechanical ventilation
- respiratory failure
- ultrasound guided
- respiratory tract
- urinary tract infection
- patient reported outcomes